Drug Trial Radar · NCT07205887
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- EyeBiotech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion. All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.
Conditions
- Neovascular Age-Related Macular Degeneration (NVAMD)
- Branch Retinal Vein Occlusion (BRVO)
Interventions
RemigromigDrug
Remigromig is a humanized antibody formulated for intravitreal administration
Aflibercept 2.0 mgDrug
Aflibercept 2.0 mg is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with Neovascular Age-Related Macular Degeneration (NVAMD). Aflibercept 2.0 mg is only administered to 2 cohorts of Incomplete Responders (IR) with NVAMD in combination with Low Dose or High Dose Remigromig.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chartTime frame: Week 12
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
Scottsdale, Arizona
Scottsdale, Arizona · Recruiting
Scottsdale, AZ
Scottsdale, Arizona · Recruiting
Glendale, California
Glendale, California · Recruiting
Glendale, CA
Glendale, California · Recruiting
Modesto, California
Modesto, California · Recruiting
Mountain View, California
Mountain View, California · Recruiting
Sacramento, CA
Sacramento, California · Recruiting
Sactamento, California
Sacramento, California · Recruiting
Sacramento, California
Sacramento, California · Recruiting
Santa Ana, California
Santa Ana, California · Recruiting
RSC Research LLC
Denver, Colorado · Recruiting
Fort Lauderdale, Florida
Fort Lauderdale, Florida · Recruiting
Fort Lauderdale, FL
Fort Lauderdale, Florida · Recruiting
Florida Retina Institute
Jacksonville, Florida · Recruiting
Florida Retina Institute
Orlando, Florida · Recruiting
Lemont, Illinois
Lemont, Illinois · Recruiting
Lemont, IL
Lemont, Illinois · Recruiting
Hagerstown, Maryland
Hagerstown, Maryland · Recruiting
Hagerstown, MD
Hagerstown, Maryland · Recruiting
Madison, Mississippi
Madison, Mississippi · Recruiting
Madison, MS
Madison, Mississippi · Recruiting
Bloomfield, New Jersey
Bloomfield, New Jersey · Recruiting
Bloomfield, NJ
Bloomfield, New Jersey · Recruiting
Long Island Vitreoretinal Consultants of NY
Great Neck, New York · Recruiting
Asheville, North Carolina
Asheville, North Carolina · Recruiting
Cary, North Carolina
Cary, North Carolina · Recruiting
North Carolina Retina Associates
Greenville, North Carolina · Recruiting
Wake Forest, NC
Wake Forest, North Carolina · Recruiting
Wake Forest, North Carolina
Wake Forest, North Carolina · Recruiting
West Columbia, SC
West Columbia, South Carolina · Recruiting
West Columbia, South Carolina
West Columbia, South Carolina · Recruiting
Germantown, Tennessee
Germantown, Tennessee · Recruiting
Knoxville, Tennessee
Knoxville, Tennessee · Recruiting
Nashville, Tennessee
Nashville, Tennessee · Recruiting
Nashville, TN
Nashville, Tennessee · Recruiting
Abilene, Texas
Abilene, Texas · Recruiting
Amarillo, Texas
Amarillo, Texas · Recruiting
Austin, Texas
Austin, Texas · Recruiting
Austin, TX
Austin, Texas · Recruiting
Bellaire, Texas
Bellaire, Texas · Recruiting
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.